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Abstract: Nonenzymatic glycation of proteins has been
implicated in various diabetic complications and age-related
disorders. Proteins undergo glycation at the N-terminus or at
the e-amino group of lysine residues. Glycation of proteins
proceeds through the stages of Schiff base formation,
conversion to ketoamine product and advanced glycation end
products. Gramicidin S, which has two ornithine residues, was
used as a model system to study the various stages of glycation
of proteins using electrospray ionization mass spectrometry. The
proximity of two ornithine residues in the peptide favors the
glycation reaction. Formation of advanced glycation end
products and diglycation on ornithine residues in gramicidin S
were observed. The formation of Schiff base adduct is reversible,
whereas the Amadori rearrangement to the ketoamine product
is irreversible. Nucleophilic amines and hydrazines can deglycate
the Schiff base adduct of glucose with peptides and proteins.
Hydroxylamine, isonicotinic acid hydrazide and aminoguanidine
effectively removed glucose from the Schiff base adduct of
gramicidin S. Hydroxylamine is more effective in deglycating the
adduct compared with isonicotinic acid hydrazide and
aminoguanidine. The observation that the hydrazines are
effective in deglycating the Schiff base adduct even in the
presence of high concentrations of glucose, may have a possible
therapeutic application in preventing complications of diabetes
mellitus. Hydrazines may be used to distinguish between the
Schiff base and the ketoamine products formed at the initial
stages of glycation.
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Nonenzymatic glycosylation or glycation of proteins is a
common post-translational modification of proteins, result-
ing from reactions between glucose and amino groups of
proteins (1). The initially formed Schiff base adduct under-
goes an irreversible Amadori rearrangement to a ketoamine
product (2). Glycation of proteins has been linked to
many pathological complications of diabetes mellitus –
retinopathy, neuropathy and nephropathy (3,4), Alzheimer’s
disease (5) and aging (6). Several reports are available on the
glycation of various proteins, notably albumin (7) hemo-
globin A (8), collagen (9), RNase A (10) and several erythro-
cytic proteins (11). Various factors have been implicated
in influencing the site and extent of glycation. The site
selectivity of glycation in proteins has been suggested to be
a consequence of the Amadori rearrangement ability of
the glycation sites (12), which in turn depends on the
microenvironment. The effect of three-dimensional struc-
ture (13) on the extent of glycation has also been reported.
The importance of buffer in influencing ketoamine forma-
tion is well studied (14). At the later stages of the glycation
reaction, oxidative cleavage of the sugar moiety leads to the
formation of AGEs such as carboxymethyllysine (CML) (15)
and pentosidine (6). CML formation is catalyzed under
oxidative conditions (16). Formation of cleavage products
such as glyoxal, methylglyoxal and 3-deoxyglucosone at
the early stages of glycation has also been reported (17).
Advanced glycation products such as carboxymethyllysine
and carboxyethyllysine have been implicated as important
intermediates in protein cross-linking reactions (18). The
accumulation of AGEs has been correlated with aging and
severity of diabetes. The CML adduct in proteins has been
established in vivo in human tissues. A wealth of experi-
mental evidence supports the hypothesis that AGEs have
an important role in the development of diabetic complica-
tions and other diseases (19). Therefore, it is important to
develop methods that can inhibit or reverse glycation at
the initial stages.
In this report we describe the use of gramicidin S, a cyclic
decapeptide, as a model for the study of protein glycation
and its reversal in the presence of nucleophilic amines.
Gramicidin S [cyclo(Leu-d-Phe-Pro-Val-Orn)2] is a struc-
turally well-defined peptide which is constrained to
adopt an antiparallel a sheet structure with cyclization
facilitated by two d-Phe-Pro a-turns. In this conformation,
the alkylamino side chains on the two ornithine residues
lie on the same phase of the a-sheet in close proximity
(20,21). We show using electrospray ionization mass
spectrometry (ESI-MS), multiple glycation and formation
of advanced glycation products in gramicidin S and also
rapid reversal of Schiff base using hydrazines such as
hydroxylamine, aminoguanidine and isonicotinic acid
hydrazide.
Materials and Methods
Gramicidin S hydrochloride and isonicotinic acid hydrazide
(INH) were purchased from Sigma chemicals. d-Glucose,
hydroxylamine hydrochloride and aminoguanidine were
purchased from Ranbaxy Chemicals. The glucose solution
was filtered through a 0.2-micron cellulose acetate filters
(Hewlett Packard Inc.) prior to addition. Hydroxylamine
hydrochloride in Milli Q water (5310–3 m) was used in all
experiments after adjusting the pH of the solution to 6 with
sodium bicarbonate. Solutions of INH and aminoguanidine
in Milli Q water (5310–3 m) were used for the deglycation
experiments.
Mass spectrometry
All electrospray spectra were recorded in the positive ion
detection mode on a Hewlett-Packard 1100 MSD model
electrospray mass spectrometer equipped with a single
quadrupole and a conventional electrospray source. Pure
water from a Milli Q apparatus (Millipore Inc.) with a
conductance of 18.2 mV was mixed with equal volume
of distilled methanol and used as the running solvent.
The solvent flow rate was 30 mL/min. Approximately
200–300 pmol of sample was injected each time for analysis.
The source temperature was kept at 3008C. Ions were
extracted with an orifice potential of 4000 V applied at the
nebulizer tip. The ionization was pneumatically assisted
using a constant flow of pure N2 gas at 10 L/min using a
Whatman nitrogen generator. The same gas was used to
maintain the nebulizer pressure at 10 bar. The nozzle
skimmer potential was kept at 20 V. The mass spectrometer
was calibrated using five m/z ions supplied by the
manufacturer across the mass range 118–2500 m/z. The
chromatographic peak width for operation was 0.18 min
The cycle time was 1.90 s/cycle and the time filter was
kept on. Data were acquired in the scan mode for 2 min
and averaged over the complete chromatogram to obtain
the mass spectrum. The charge states were determined
using the isotopic distribution of the peaks and also from
the difference between the peak values of the protonated
and sodiated species. The major species observed is the
doubly charged species in all cases.
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In vitro glycation
In vitro glycation of gramicidin S was carried out by
incubating the samples in glucose (analytical grade) solution
at room temperature. The glycation mixture was made in a
1 : 1 mixture of methanol/water (v/v) with a final concentra-
tion of 2.5310–3 m gramicidin S, 5.0310–1 m glucose and
2.0310–2 m sodium bicarbonate solution at pH 8.5. The
rate of glycation was monitored at different intervals using
electrospray ionization mass spectrometry. Deglycation of
Schiff base using hydroxylamine was achieved by treating
the samples with equal volumes of 5310–3 m hydroxyl-
amine solution and the samples were analyzed immediately
using ESI-MS. In the cases of INH and aminoguanidine,
deglycation of the Schiff base was done by treating the
samples with equal volumes of 5310–3 m solutions and
incubating at 378C for 4 h.
Oxime formation
Gramicidin incubated with glucose for 24 h was treated
with excess hydroxylamine. The mixture was heated to
708C in a water bath for 1 h and then analyzed using ESI-MS.
A similar procedure was followed for the preparation of
the aminoguanidine derivative.
Results
Glycation of gramicidin S
The ESI-MS spectrum (Fig. 1a) of gramicidin S shows the
presence of two charge states [M+H]+ and [M+2H]2+ at m/z
1141.8 and 571.5, respectively. Upon incubation of grami-
cidin S with glucose at pH 8.5, glycation proceeds rapidly
with<50% singly glycated species [B] being observed at 3 h.
Table 1 summarizes the species detected by ESI-MS in the
glycation mixture. The presence of two ornithine residues at
proximal positions facilitates the glycation reaction. Multi-
ply glycated species were observed on prolonged incubation.
A significant amount of doubly glycated species [C] was
observed after 6 h of incubation. Hydroxylamine was used to
differentiate the Schiff base and ketoamine product. The
former was completely converted to glucose and peptide by
nucleophilic amines, whereas the later was unaffected. The
sample incubated for 6 h, on treatment with hydroxylamine
underwent complete deglycation indicating that the total
‘glycated product’ exists solely as the Schiff base adduct at
this stage.
The glycation product obtained after 24 h (Fig. 1b) of
incubation with glucose, on treatment with hydroxylamine
showed retention of some glycation, indicating the forma-
tion of ketoamine product. Similar results were obtained
on treatment with aminoguanidine and isonicotinic acid
hydrazide. Addition of excess hydroxylamine to the sample
formed a significant amount of oxime on heating. In Fig. 2,
the peak at m/z 571.6 corresponds to the doubly protonated
[M+2H]2+ gramicidin S. The peak at m/z 582.7 corresponds
to the proton and sodium ion adduct [M+H+Na]2+ of
gramicidin S. The peaks at m/z 652.5 corresponds to the
doubly charged state of singly glycated peptide. The peak at
m/z 660.0 corresponds to the doubly charged state of the
oxime of the singly glycated species. Similarly, the peaks at
m/z 741.1 and 748.5 correspond to the doubly charged
states of the mono- and bisoximes of the doubly glycated
gramicidin S. Formation of oxime derivatives conforms that
the singly and doubly glycated species are present as the
ketoamine products at this stage. Formation of ketoamine
product increases with time. The time course of glycation
of gramicidin S is shown as inserts in Fig. 1b. The insert
on the left shows the time course of the formation of
singly glycated species and the insert on the right shows
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Figure 1. ESI mass spectra of (a) gramicidin S and gramicidin S
incubated for (b) 1 day, (c) 100 days and (d) 140 days. The species are
listed in Table 1. Insets in (b) show the ratio of singly glycated to
native gramicidin (Pg/P) up to 30 h (left) and the ratio of doubly to
singly glycated gramicidin (P2g/Pg) up to 200 h (right).
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the time course of formation of the doubly glycated
species. The rate of formation of singly glycated species is
greater than that of doubly glycated species.
Continued incubation of gramicidin S with glucose
resulted in the appearance of triply glycated species D, at
30 h of incubation. After 72 h of incubation, the spectrum
shows the complete absence of native gramicidin and
significant amount of triply glycated species in which
there is double glycation on one of the ornithine residues
(figure not shown). Treatment of this sample with
hydroxylamine did not result in the deglycation of
species D, indicating that D is a ketoamine product.
The mass spectrum of the sample incubated for 100 days
(Fig. 1c) shows the presence of advanced glycation products
CML [F, H] and CEL [G, I]. After 140 days of incubation,
the major species observed (Fig. 1d) was the triply glycated
species D. Significant amounts of species E (Table 1), in
which there is double glycation on both the ornithine
residues, were also observed. Species D and E were retained
on treatment with hydroxylamine indicating that they are
ketoamine adducts. At this time, singly glycated gramicidin
was completely absent.
Reversal of glycation in gramicidin S
Addition of hydroxylamine to the gramicidin sample after
6 h of incubation with glucose (Fig. 3a) resulted in complete
deglycation of the glucose adducts (Fig. 3b). Similarly, on
passing through a reverse-phase C18 liquid chromatography
column complete reversal of glycation was observed.
Treatments with INH or aminoguanidine (Fig. 3c) also
caused deglycation of the glucose adduct but hydroxylamine
was found to be more effective. Prolonged incubation of
the glycated peptide with INH or aminoguanidine showed
that deglycation using these reagents improved with time.
Partial deglycation was observed in samples incubated with
sugar for more than 24 h on treatment with hydroxylamine,
INH and aminoguanidine.
Discussion
Glycation of gramicidin S
Glycation of gramicidin S proceeds rapidly in glucose
solution with the singly glycated species being observed
within 30 min of incubation. At 3 h of incubation, the
intensity of the singly glycated species is <50% that of
the native peptide. Treatment of hydroxylamine to the
sample incubated for 6 h results in the complete deglycation
of the glycated species, indicating that the glycated species
at this stage exists exclusively as the Schiff base. In earlier
reports, the characterization and quantitation of Schiff base
adducts were carried out using UV absorption or by
measuring the radioactivity of the labeled derivatives of
the glycated proteins (22). Here we have shown ESI-MS
analysis can be used to quantify the Schiff base adduct
without the need for derivatization. Mass spectrometric
Table 1. List of species present in the glycation mixture of gramicidin S
Code Component
Calcd
Mr
Peaks obsd
m/z Charged species present
A Gramcidin S 1141 1141.8, 571.5 [M+H]+, [M+2H]2+
B Gramicidin S+1 glucose 1303 652.5, 663.5 [M+2H]2+, [M+H+Na]2+
C Gramicidin S+2 glucose 1465 733.5, 744.6 [M+2H]2+, [M+H+Na]2+
D Gramicidin S+3 glucose 1627 814.5825.7 [M+2H]2+, [M+H+Na]2+
E Gramicidin S+4 glucose 1789 895.5 [M+2H]2+
F CML of C 1361 681.5 [M+2H]2+
G CEL of C 1375 688.7 [M+2H]2+
H CML of D 1523 762.5, 784.5 [M+2H]2+, [M+H+Na]2+
I CEL of D 1537 769.5 [M+2H]2+
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Figure 2. ESI mass spectrum of glycated gramicidin heated with
hydroxylamine. Oxime derivatives of singly and doubly glycated
gramicidin are observed as doubly charged species.
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techniques such as ESI-MS and MALDI have been used
for quantitation of total glycation, to find sites of glycation
and for the characterization of AGEs. Application of
ESI-MS for the quantitation of glycated hemoglobin
(23,24), identification and quantitation of AGEs such as
CML, pentosidine, glyoxal lysine dimer and methylglyoxal
lysine dimer in human serum proteins (25) has been
reported. Application of MALDI for the identification and
quantitation of the various AGEs in the reaction of glucose
with proteins has also been reported (26). Lapolla et al.
(27,28) reported the application of MALDI for the character-
ization of glycation and glycoxidation of globins.
In this study, quantitation of ketoamine product is also
shown using ESI-MS. On treatment with hydroxylamine,
partial deglycation was observed in samples incubated for 12
and 24 h. This would imply that the Amadori rearrangement
has taken place to some extent at this time to give the
ketoamine product, which does not undergo deglycation
with hydroxylamine. The glycated product obtained after
24 h of incubation with glucose was treated with excess
hydroxylamine and warmed. The glycated adducts formed
the corresponding oxime, confirming that this was indeed
the ketoamine (Fig. 2). Aminoguanidine also formed the
corresponding derivative showing that the hydrazines
can be used to differentiate the two stages of glycation.
Earlier studies used 2,4-dinitrophenylhydrazine (29) and
phenylhydrazine (30) for the quantitative determination
of reactive carbonyl groups in proteins and peptides. The UV
absorption of phenylhydrazone derivatives at 370 nm is
used for the quantitation of carbonyl groups.
The rate of formation of doubly glycated species is slow
compared with that of singly glycated species. This could
be because of the glycation at one of the ornithine reduces
its catalytic effect on the glycation of the other ornithine.
Further incubation (30 h) of the peptide with sugar resulted
in the formation of glycated peptide (D) with three glucose
molecules bound to the peptide indicating double glycation
on one of the ornithine residues. The rate of formation of
the triply glycated species was found to be very slow
compared with the formation of singly and doubly glycated
species, implying that diglycation on the same residue is
a very slow process. A similar observation was made
Blakytny et al. (31) in the diglycation of N-acetyl lysine.
The Amadori rearrangement of the bisglucose adduct
(two glucose molecules bound to the same ornitihine
residue) was found to be faster than that of mono adduct.
This could presumably be due to the formation of
immonium ion in the Schiff base of bis-adduct (which is
the rate limiting step in the Amadori rearrangement
under the reaction conditions) which facilitates the forma-
tion of the enolamine and ketoamine (Fig. 4). The ESI-MS of
the sample in which gramicidin S was incubated with
glucose for 100 days (Fig. 1c) reveals that the major species
is the triply glycated gramicidin S (D). Significant amounts
of advanced glycation end products CML (F, H) and CEL
(G, I) of the species C and D were also observed. The pH
conditions used in this study (pH 8.5) facilitate the forma-
tion of CML. The rate of formation of CML from the
ketoamine product of N-formyl-N-fructoselysine is reported
to be higher at higher pH (15). This is analogous to the
oxidative degradation of sugars in alkali. Oxidative degrada-
tion of sugars is known to proceed by a free radical
mechanism (32).
The ESI-MS spectrum of the sample incubated for
140 days (Fig. 1d) shows significant amounts of species E,
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Figure 3. ESI mass spectra of glycated gramicidin: (a) incubated with
glucose for 6 h, (b) after treatment with hydroxylamine and (c) after
treatment with aminoguanidine. Species observed are listed in
Table 1.
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in which four glucose molecules are bound to the peptide.
A maximum of four molecules of glucose can be bound to
the peptide when both the ornithines are bound to two
glucose residues. Observation of species E implies diglyca-
tion on both the ornithine residues of the peptide, which
may be facilitated by the presence of two ornithine groups
in the peptide at proximal positions. The rate of formation
of E was found to be very slow which could be due to the
reduction in catalytic effect of the proximal ornithine
residue, which is diglycated.
Reversal of glycation
The initial glycation product is a Schiff base adduct
(aldimine) of glucose with the peptide, which undergoes
Amadori rearrangement to give the ketoamine product
in a slow irreversible process (12). The Schiff base adduct
exists in dynamic equilibrium with the glucose in the
medium. Because the Schiff base adduct formation is a
reversible reaction (Fig. 5), the removal of sugar by column
chromatography (or dialysis in proteins) shifts the equi-
librium (33) resulting in deglycation of the peptide glucose
adduct. Various agents such as aminoguanidine (34–36),
d-lysine (37,38), desferrioxamine (39), d-penicillamine (40),
thiamine pyrophosphate and pyridoxamine (41), and aryl
ureido and aryl carboxamido phenoxy isobutyric acids (42)
phenyl 4,5-dimethylthiazolium chloride (ALT 711) (43),
amadoriases (44), chelators, sulfhydryl compounds and
antioxidants (45) have been investigated in both in vitro
and in vivo to interact at various stages of glycation.
Among the various inhibitors of glycation, aminoguani-
dine has been studied extensively with specific focus on its
possible clinical role in the treatment of chronic diabetic
complications. Brownlee et al. (34) reported inhibition of
advanced glycosylation product formation and glucose-
derived collagen cross-linking in vitro using aminoguani-
dine. Interaction of aminoguanidine at the various stages of
the glycation reaction has been reported. Aminoguanidine
reacts with dicarbonyl compounds such as glyoxal, methyl-
glyoxal and deoxyglucosone, which are formed from the
oxidative degradation of free sugar and with the dicarbonyl
compounds formed from the post Amadori glycation
product of proteins (Fig. 6) (36). It has also been reported
to interact with the ketoamine stage of the glycation
reaction and forms substituted Amadori product and thus
prevents the formation of glucose-derived cross-linked
products (34). Interaction of aminoguanidine at the initial,
Schiff base stage of glycation has not been studied.
In our study, hydrazines are used to cause reversal of
glycation at the Schiff base stage. Hydrazines are effective in
deglycating the Schiff base adduct at equimolar concentra-
tion of the glycated species. Hydroxylamine, which is a
strong nucleophile, causes specific deglycation of the Schiff
base adduct even in the presence of excess glucose.
Nucleophilic attack of hydroxylamine (transglycosylation)
on the Schiff base presumably releases the glucose as
the glucose oxime. (Our attempts to characterize the
glucose oxime formed in the transglycosylation reaction
were unsuccessful because of the poor ionization of the
glucose oxime under the ESI conditions used in the study.)
Although there is a competing reaction between the
free sugar in the reaction mixture and the hydroxylamine,
the rate of transglycosylation is higher than the reaction of
the free sugar, resulting in effective deglycation with
hydroxylamine. Indeed, the rate of nucleophilic attack of
semicarbazide on Schiff bases has been shown to be
several orders of magnitude more rapid than the attack on
the free aldehydes (Fig. 7). This large rate difference has
been attributed to the greater basicity of the Schiff base
compared with the aldehydes (46).
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In order to examine the generality of the mechanism of
transglycosylation, the effects of isonicotinic acid hydrazide
(INH) and aminoguanidine on glycation were studied.
INH is an antituberculosis drug that is known to interfere
with pyridoxal phosphate (PLP) containing enzyme func-
tions by reacting with PLP Schiff bases (47). In our studies
we note that INH and aminoguanidine were also effective
in deglycation of the glucose adduct at the Schiff base stage.
Aminoguanidine and INH are poorer nucleophiles than
hydroxylamine, resulting in slower transglycosylation rates
compared with hydroxylamine. However, the transglyco-
sylation is faster than the reaction of INH/aminoguanidine
with free sugar resulting in deglycation of the peptide
glucose adduct. Hence, addition of aminoguanidine or INH
to the glycation reaction mixture results in significant
reduction in the intensity of the glycated species indicating
that these are effective deglycating agents at the Schiff
base stage of the glycation reaction. Deglycation of glycated
peptide at the Schiff base stage using the hydrazines
restores the native peptide, a process that is not achieved
by deglycation at the advanced glycation stages using the
other deglycating agents such as antioxidants.
Conclusions
Gramicidin S is shown to be a good model system to study
the various stages of glycation reaction in proteins. ESI-MS
is a convenient tool to follow the glycation reaction.
Quantitation of Schiff base and the ketoamine adduct,
characterization of AGEs, diglycation of ornithine residues
and reversal of glycation using nucleophilic hydrazines
have been studied using ESI-MS. The mode of action of
hydrazines involves deglycation of the Schiff base adduct
rather than reaction at the level of the ketoamine, thus
terminating the deleterious effect of glycation at a reversible
stage. The effectiveness of INH, a clinically used anti-
tuberculosis drug is noteworthy. Compounds with similar
functional groups can be screened in order to develop a
viable therapeutic agent. Hydrazines may also be used to
distinguish between the Schiff base and ketoamine adduct.
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